Novocure's Phase 3 ENGOT-ov50 / GOG-3029 / INNOVATE-3 Trial Of Tumor Treating Fields Together With Paclitaxel In Patients With Platinum-Resistant Ovarian Cancer Did Not Meet Its Primary Endpoint Of Overall Survival At The Final Analysis
Portfolio Pulse from Benzinga Newsdesk
Novocure's Phase 3 trial of Tumor Treating Fields (TTFields) in combination with paclitaxel for platinum-resistant ovarian cancer did not meet its primary endpoint of overall survival. Patients receiving TTFields therapy plus paclitaxel showed a median overall survival of 12.2 months, compared to 11.9 months for those treated with paclitaxel alone. The therapy was well-tolerated with no added systemic toxicities.
August 28, 2023 | 11:06 am
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Novocure's Phase 3 trial of TTFields did not meet its primary endpoint, which may negatively impact investor sentiment and the company's stock price in the short term.
Clinical trial results are a significant driver of biotech and pharmaceutical company valuations. The failure to meet the primary endpoint in a Phase 3 trial is a major setback, as it may indicate that the treatment is not as effective as hoped. This could lead to a decline in Novocure's stock price as investors reassess the potential profitability of the TTFields therapy.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100